Aravive, Inc. (25)

Browse by Contract Category

Contracts

Consulting Agreement, dated December 31, 2020, between the Company and Ray Tabibiazar (Filed With SEC on January 4, 2021)
Collaboration and License Agreement between Aravive, Inc. and 3D Medicines Inc. dated November 6, 2020 (Filed With SEC on November 10, 2020)
Amendment to Offer Letter dated as of April 8, 2020 by and between the Company and Gail McIntyre (Filed With SEC on April 9, 2020)
Purchase Agreement, dated November 27, 2019, by and among Aravive, Inc., Piper Jaffray & Co. and Cantor Fitzgerald & Co (Filed With SEC on November 27, 2019)
Option Agreement dated April 8, 2020 by and between the Company and Robert Hoffman (Filed With SEC on April 9, 2020)
Option Agreement dated April 8, 2020 by and between the Company and Jay Shepard (Filed With SEC on April 9, 2020)
Option Agreement dated April 8, 2020 by and between the Company and Srini Akkaraju (Filed With SEC on April 9, 2020)
Separation Agreement dated April 8, 2020 between the Company and Rekha Hemrajani (Filed With SEC on April 9, 2020)
Investment Agreement, dated as of April 6, 2020, by and among the Company, Eshelman Ventures, LLC, and, solely for purposes of Article IV and Article V of the Investment... (Filed With SEC on April 9, 2020)
Offer Letter, dated March 26, 2020, between Vinay Shah and Aravive, Inc (Filed With SEC on March 27, 2020)
Form of 2019 Equity Incentive Plan Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement (Filed With SEC on March 27, 2020)
Offer Letter, dated March 26, 2020 between Gail McIntyre and Aravive, Inc (Filed With SEC on March 27, 2020)
Description of Capital Securities (Filed With SEC on March 27, 2020)
Offer Letter, dated January 8, 2020, between Rekha Hemrajani and Aravive, Inc (Filed With SEC on January 9, 2020)
Separation Agreement, dated January 9, 2020, between Jay Shepard and Aravive, Inc (Filed With SEC on January 9, 2020)
Consulting Agreement, dated January 9, 2020, between Jay Shepard and Aravive, Inc (Filed With SEC on January 9, 2020)
Equity Distribution Agreement, dated as of March 26, 2019, between Aravive, Inc. and Piper Jaffray & Co (Filed With SEC on March 26, 2019)
Non-Employee Director Compensation Policy, as amended January 3, 2019 (Filed With SEC on March 15, 2019)
First Amendment to 2014 Equity Incentive Plan (Filed With SEC on March 6, 2019)
Amendment to Jay Shepard Offer Letter dated as of February 28, 2019 (Filed With SEC on March 6, 2019)
Amendment to Jay Shepard Offer Letter dated as of February 6, 2019 (Filed With SEC on February 12, 2019)
Severance Agreement dated May 31, 2018 and amendment thereto dated September 24, 2018 between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)
Offer Letter dated January 1, 2017 by and between Aravive Biologics, Inc. and Gail McIntyre (Filed With SEC on February 12, 2019)
Severance Agreement dated May 31, 2018 and amendment thereto dated September 24, 2018 between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)
Offer Letter dated February 1, 2017 and the amendment thereto dated May 30, 2018 by and between Aravive Biologics, Inc. and Vinay Shah (Filed With SEC on February 12, 2019)